IL-17A and IL-17F orchestrate macrophages to promote lung cancer

[1]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[2]  I. Berindan‐Neagoe,et al.  The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches , 2020, Cellular Oncology.

[3]  S. Molina-Pinelo,et al.  Epigenetics of lung cancer: a translational perspective , 2019, Cellular Oncology.

[4]  D. Galetta,et al.  The therapeutic potential of mesenchymal stem cells in lung cancer: benefits, risks and challenges , 2019, Cellular Oncology.

[5]  Arash Salmaninejad,et al.  Tumor-associated macrophages: role in cancer development and therapeutic implications , 2019, Cellular Oncology.

[6]  Tianmin Xu,et al.  Macrophage Polarization in the Development and Progression of Ovarian Cancers: An Overview , 2019, Front. Oncol..

[7]  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer; Nivolumab and Ipilimumab in Advanced Melanoma; Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma; Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy; Combined Nivolumab and Ipilimumab or Monotherap , 2018, The New England journal of medicine.

[8]  I. Melero,et al.  Cytokines in clinical cancer immunotherapy , 2018, British Journal of Cancer.

[9]  T. Salo,et al.  Extracellular interleukin‐17F has a protective effect in oral tongue squamous cell carcinoma , 2018, Head & neck.

[10]  M. Rasool,et al.  Interleukin 17 under hypoxia mimetic condition augments osteoclast mediated bone erosion and expression of HIF-1α and MMP-9. , 2018, Cellular immunology.

[11]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[12]  R. Liu,et al.  Corrigendum to “New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy” , 2018, Journal of immunology research.

[13]  A. Engelbrecht,et al.  Role of PKM2 in directing the metabolic fate of glucose in cancer: a potential therapeutic target , 2018, Cellular Oncology.

[14]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[15]  Stephen Broderick,et al.  Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.

[16]  C. Creighton,et al.  IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer , 2018, Cancer Immunology Research.

[17]  S. Chouaib,et al.  The role of hypoxia in shaping the recruitment of proangiogenic and immunosuppressive cells in the tumor microenvironment , 2018, Contemporary oncology.

[18]  F. Blanco-Favéla,et al.  IL-17-differentiated macrophages secrete pro-inflammatory cytokines in response to oxidized low-density lipoprotein , 2017, Lipids in Health and Disease.

[19]  R. Reis,et al.  Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells , 2017, Oncotarget.

[20]  L. Abusleme,et al.  IL-17: overview and role in oral immunity and microbiome. , 2017, Oral diseases.

[21]  G. Freeman,et al.  Interleukin‐17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD‐1 Blockade , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  M. Veldhoen.  Interleukin 17 is a chief orchestrator of immunity , 2017, Nature Immunology.

[23]  Yingwei Wang,et al.  IL-17-triggered downregulation of miR-497 results in high HIF-1α expression and consequent IL-1β and IL-6 production by astrocytes in EAE mice , 2017, Cellular & Molecular Immunology.

[24]  C. R. Correia,et al.  The influence of surface modified poly(l-lactic acid) films on the differentiation of human monocytes into macrophages. , 2017, Biomaterials science.

[25]  A. Longatto-Filho,et al.  HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors , 2017, Theranostics.

[26]  R. Liu,et al.  Corrigendum Corrigendum : , 2017 .

[27]  A. Bhatt,et al.  Role of interleukin-6 in cancer progression and therapeutic resistance , 2016, Tumor Biology.

[28]  M. Wang,et al.  Role of IL-17A rs2275913 and IL-17F rs763780 polymorphisms in risk of cancer development: an updated meta-analysis , 2016, Scientific Reports.

[29]  Hui Wang,et al.  Interleukin-17 potently increases non-small cell lung cancer growth. , 2016, Molecular medicine reports.

[30]  V. Kuchroo,et al.  Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions. , 2015, Immunity.

[31]  E. Jordanova,et al.  FoxP3+ and IL-17+ cells are correlated with improved prognosis in cervical adenocarcinoma , 2015, Cancer Immunology, Immunotherapy.

[32]  R. Reis,et al.  Glucose Addiction in Cancer Therapy: Advances and Drawbacks. , 2015, Current drug metabolism.

[33]  Fang Liu,et al.  Interleukin-17-induced EMT promotes lung cancer cell migration and invasion via NF-κB/ZEB1 signal pathway. , 2015, American journal of cancer research.

[34]  H. Spits,et al.  The biology of innate lymphoid cells , 2015, Nature.

[35]  Yuanyuan Sun,et al.  IL-17/miR-192/IL-17Rs Regulatory Feedback Loop Facilitates Multiple Myeloma Progression , 2014, PloS one.

[36]  Kristina M. Little,et al.  IL-17A Influences Essential Functions of the Monocyte/Macrophage Lineage and Is Involved in Advanced Murine and Human Atherosclerosis , 2014, The Journal of Immunology.

[37]  Y. Takei,et al.  Interleukin-17 Induces an Atypical M2-Like Macrophage Subpopulation That Regulates Intestinal Inflammation , 2014, PloS one.

[38]  M. Caetano,et al.  T helper 17 cells play a critical pathogenic role in lung cancer , 2014, Proceedings of the National Academy of Sciences.

[39]  Huafeng Zhang,et al.  Hypoxia and cancer cell metabolism. , 2014, Acta biochimica et biophysica Sinica.

[40]  K. Tizaoui,et al.  Interleukin-17A and -17F genes polymorphisms in lung cancer. , 2014, Cytokine.

[41]  S. McKeown,et al.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. , 2014, The British journal of radiology.

[42]  F. Baltazar,et al.  The Monocarboxylate Transporter Inhibitor α-Cyano-4-Hydroxycinnamic Acid Disrupts Rat Lung Branching , 2013, Cellular Physiology and Biochemistry.

[43]  A. Sikora,et al.  Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. , 2013, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  J. Xu,et al.  Mast cells expressing interleukin 17 in the muscularis propria predict a favorable prognosis in esophageal squamous cell carcinoma , 2013, Cancer Immunology, Immunotherapy.

[45]  D. Straus.  TNFα and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells , 2013, Molecular Cancer.

[46]  F. Baltazar,et al.  Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin , 2013, Journal of Bioenergetics and Biomembranes.

[47]  M. Ramos-Nino.  The Role of Chronic Inflammation in Obesity-Associated Cancers , 2013, ISRN oncology.

[48]  Xuexian O Yang,et al.  A Protective Role by Interleukin-17F in Colon Tumorigenesis , 2012, PloS one.

[49]  A. Rosenwald,et al.  Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance , 2012, Haematologica.

[50]  Q. Kong,et al.  Effects of IL-17A on the occurrence of lung adenocarcinoma , 2011, Cancer biology & therapy.

[51]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[52]  A. Chang,et al.  Intratumoral Expression of IL-17 and Its Prognostic Role in Gastric Adenocarcinoma Patients , 2011, International journal of biological sciences.

[53]  M. Banerjee,et al.  Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. , 2009, Blood.

[54]  W. Zou,et al.  Endogenous IL-17 contributes to reduced tumor growth and metastasis. , 2009, Blood.

[55]  Frann Bennett,et al.  The Human IL-17F/IL-17A Heterodimeric Cytokine Signals through the IL-17RA/IL-17RC Receptor Complex , 2008, The Journal of Immunology.

[56]  Y. Rojanasakul,et al.  Inflammation and Lung Cancer: Roles of Reactive Oxygen/Nitrogen Species , 2008, Journal of toxicology and environmental health. Part B, Critical reviews.

[57]  Scott R. Presnell,et al.  Identification of the IL-17 Receptor Related Molecule IL-17RC as the Receptor for IL-17F , 2007, The Journal of Immunology.

[58]  Jiannis Ragoussis,et al.  Concordant Regulation of Gene Expression by Hypoxia and 2-Oxoglutarate-dependent Dioxygenase Inhibition , 2006, Journal of Biological Chemistry.

[59]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[60]  K. Ha,et al.  Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells , 2005, Experimental & Molecular Medicine.

[61]  Yulan He,et al.  IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. , 1998, Journal of immunology.

[62]  Hankui Chen,et al.  Interleukin‐17 acts as double‐edged sword in anti‐tumor immunity and tumorigenesis , 2017, Cytokine.

[63]  N. Liao,et al.  An updated meta-analysis , 2017 .

[64]  P. Mahadevan,et al.  An overview , 2007, Journal of Biosciences.

[65]  G. Collins.  The next generation. , 2006, Scientific American.